PRESILLION™ CoCr Coronary Stent Offers Physicians Bare Metal Stent Option
Warren, NJ (May 13, 2008) – Cordis Corporation today announced the availability of the PRESILLION™ Cobalt Chromium (CoCr) Coronary Stent in Europe. A bare metal stent, the PRESILLION™ stent provides flexibility that delivers the stent through the arteries and conformability and scaffolding that adapts to the vessel when deployed.
“The PRESILLION™ Stent had a very smooth delivery and passed the calcified area proximal to the lesion quickly,” said Professor Eberhard Grube, M.D., Chief of Cardiology, Heart Center Siegburg, in Sieburg, Germany, who recently performed a case with the PRESILLION™ Stent. “The final angiogram showed the excellent conformability and scaffolding of the PRESILLION™ Stent to the vessel walls." Professor Grube has no financial relationship with Cordis Corporation.
The PRESILLION™ Stent consists of alternating rings of narrow and wide struts that are optimized to give excellent flexibility with the narrow struts while maintaining optimal radial strength with the wide struts. The unique stent design includes an adaptive closed cell architecture that is capable of differential lengthening. This enables the stent to be flexible in the unexpanded configuration, and support the vessel while conforming to its curvature in the expanded configuration.
“In our role as a solutions provider in the cath lab, we are pleased to provide another stent option for interventional cardiologists in Europe,” said Staffan Ternstrom, President, Cordis Europe. “The PRESILLION™ Stent is a great complement to our CYPHER® Select Plus™ Sirolimus-eluting Coronary Stent. It is highly deliverable and very flexible which are two characteristics important to physicians today.”
The PRESILLION™ Stent is available in lengths that range from 8-33 mm and in a variety of diameter sizes from 2.5-4.0 mm.
“The PRESILLION™ Stent is part of our goal to provide interventional cardiologists with the right combination of products and services to help optimize outcomes in their practices,” said Ternstrom.
Cordis Corporation is the exclusive global distributor of the PRESILLION™ stent, which is designed and manufactured by Medinol Ltd, Israel. PRESILLION™ is a trademark of Cordis Corporation. The product received CE mark in March 2008.
About Cordis Corporation
Cordis Corporation, a Johnson & Johnson company, is a worldwide leader in the development and manufacture of interventional vascular technology. Through the company's innovation, research and development, Cordis partners with interventional cardiologists worldwide to treat millions of patients who suffer from vascular disease. More information about Cordis Corporation can be found at www.cordis.com.
# # #
PRESILLION™ CoCr Coronary Stent Offers Physicians Bare Metal Stent Option
Warren, NJ (May 13, 2008) – Cordis Corporation today announced the availability of the PRESILLION™ Cobalt Chromium (CoCr) Coronary Stent in Europe. A bare metal stent, the PRESILLION™ stent provides flexibility that delivers the stent through the arteries and conformability and scaffolding that adapts to the vessel when deployed.
“The PRESILLION™ Stent had a very smooth delivery and passed the calcified area proximal to the lesion quickly,” said Professor Eberhard Grube, M.D., Chief of Cardiology, Heart Center Siegburg, in Sieburg, Germany, who recently performed a case with the PRESILLION™ Stent. “The final angiogram showed the excellent conformability and scaffolding of the PRESILLION™ Stent to the vessel walls." Professor Grube has no financial relationship with Cordis Corporation.
The PRESILLION™ Stent consists of alternating rings of narrow and wide struts that are optimized to give excellent flexibility with the narrow struts while maintaining optimal radial strength with the wide struts. The unique stent design includes an adaptive closed cell architecture that is capable of differential lengthening. This enables the stent to be flexible in the unexpanded configuration, and support the vessel while conforming to its curvature in the expanded configuration.
“In our role as a solutions provider in the cath lab, we are pleased to provide another stent option for interventional cardiologists in Europe,” said Staffan Ternstrom, President, Cordis Europe. “The PRESILLION™ Stent is a great complement to our CYPHER® Select Plus™ Sirolimus-eluting Coronary Stent. It is highly deliverable and very flexible which are two characteristics important to physicians today.”
The PRESILLION™ Stent is available in lengths that range from 8-33 mm and in a variety of diameter sizes from 2.5-4.0 mm.
“The PRESILLION™ Stent is part of our goal to provide interventional cardiologists with the right combination of products and services to help optimize outcomes in their practices,” said Ternstrom.
Cordis Corporation is the exclusive global distributor of the PRESILLION™ stent, which is designed and manufactured by Medinol Ltd, Israel. PRESILLION™ is a trademark of Cordis Corporation. The product received CE mark in March 2008.
About Cordis Corporation
Cordis Corporation, a Johnson & Johnson company, is a worldwide leader in the development and manufacture of interventional vascular technology. Through the company's innovation, research and development, Cordis partners with interventional cardiologists worldwide to treat millions of patients who suffer from vascular disease. More information about Cordis Corporation can be found at www.cordis.com.
# # #